[go: up one dir, main page]

GB201709444D0 - Dosage regime - Google Patents

Dosage regime

Info

Publication number
GB201709444D0
GB201709444D0 GBGB1709444.2A GB201709444A GB201709444D0 GB 201709444 D0 GB201709444 D0 GB 201709444D0 GB 201709444 A GB201709444 A GB 201709444A GB 201709444 D0 GB201709444 D0 GB 201709444D0
Authority
GB
United Kingdom
Prior art keywords
dosage regime
regime
dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1709444.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADC Therapeutics SA
MedImmune Ltd
Original Assignee
ADC Therapeutics SA
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADC Therapeutics SA, MedImmune Ltd filed Critical ADC Therapeutics SA
Priority to GBGB1709444.2A priority Critical patent/GB201709444D0/en
Publication of GB201709444D0 publication Critical patent/GB201709444D0/en
Priority to PCT/EP2018/065873 priority patent/WO2018229222A1/en
Priority to UAA202100090A priority patent/UA127900C2/en
Priority to AU2018285562A priority patent/AU2018285562B2/en
Priority to MX2019015042A priority patent/MX2019015042A/en
Priority to ES18732041T priority patent/ES2988683T3/en
Priority to EP18732041.1A priority patent/EP3638373B1/en
Priority to US16/622,649 priority patent/US11318211B2/en
Priority to BR112019026564-3A priority patent/BR112019026564A2/en
Priority to PL18732041.1T priority patent/PL3638373T3/en
Priority to CA3064804A priority patent/CA3064804A1/en
Priority to JP2019569479A priority patent/JP7145891B2/en
Priority to KR1020197037482A priority patent/KR102442736B1/en
Priority to NZ759283A priority patent/NZ759283B2/en
Priority to ZA2019/07613A priority patent/ZA201907613B/en
Priority to US17/699,065 priority patent/US11938192B2/en
Priority to JP2022148738A priority patent/JP2022191244A/en
Priority to US17/938,193 priority patent/US20230106885A1/en
Priority to JP2024195841A priority patent/JP2025024041A/en
Ceased legal-status Critical Current

Links

GBGB1709444.2A 2017-06-14 2017-06-14 Dosage regime Ceased GB201709444D0 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
GBGB1709444.2A GB201709444D0 (en) 2017-06-14 2017-06-14 Dosage regime
NZ759283A NZ759283B2 (en) 2018-06-14 Dosage regimes for the administration of an anti-cd19 adc
BR112019026564-3A BR112019026564A2 (en) 2017-06-14 2018-06-14 dosing regimens for administration of an anti-cd19 adc
CA3064804A CA3064804A1 (en) 2017-06-14 2018-06-14 Dosage regimes for the administration of an anti-cd19 adc
AU2018285562A AU2018285562B2 (en) 2017-06-14 2018-06-14 Dosage regimes for the administration of an anti-CD19 ADC
MX2019015042A MX2019015042A (en) 2017-06-14 2018-06-14 Dosage regimes for the administration of an anti-cd19 adc.
ES18732041T ES2988683T3 (en) 2017-06-14 2018-06-14 Dosage guidelines for the administration of an anti-CD19 CAF
EP18732041.1A EP3638373B1 (en) 2017-06-14 2018-06-14 Dosage regimes for the administration of an anti-cd19 adc
US16/622,649 US11318211B2 (en) 2017-06-14 2018-06-14 Dosage regimes for the administration of an anti-CD19 ADC
PCT/EP2018/065873 WO2018229222A1 (en) 2017-06-14 2018-06-14 Dosage regimes for the administration of an anti-cd19 adc
PL18732041.1T PL3638373T3 (en) 2017-06-14 2018-06-14 Dosing regimens for anti-CD19 ADC administration
UAA202100090A UA127900C2 (en) 2017-06-14 2018-06-14 Dosage regimes for the administration of an anti-cd19 adc
JP2019569479A JP7145891B2 (en) 2017-06-14 2018-06-14 Dosing Regimens for Administering Anti-CD19 ADCs
KR1020197037482A KR102442736B1 (en) 2017-06-14 2018-06-14 Dosage regime for administration of anti-CD19 ADCs
ZA2019/07613A ZA201907613B (en) 2017-06-14 2019-11-18 Dosage regimes for the administration of an anti-cd19 adc
US17/699,065 US11938192B2 (en) 2017-06-14 2022-03-18 Dosage regimes for the administration of an anti-CD19 ADC
JP2022148738A JP2022191244A (en) 2017-06-14 2022-09-20 Dosage regimes for administration of anti-cd19 adc
US17/938,193 US20230106885A1 (en) 2017-06-14 2022-10-05 Dosage regime
JP2024195841A JP2025024041A (en) 2017-06-14 2024-11-08 Dosing regimens for administering anti-CD19 ADCs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1709444.2A GB201709444D0 (en) 2017-06-14 2017-06-14 Dosage regime

Publications (1)

Publication Number Publication Date
GB201709444D0 true GB201709444D0 (en) 2017-07-26

Family

ID=59358162

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1709444.2A Ceased GB201709444D0 (en) 2017-06-14 2017-06-14 Dosage regime

Country Status (1)

Country Link
GB (1) GB201709444D0 (en)

Similar Documents

Publication Publication Date Title
EP3638658C0 (en) Pharmaceutical compounds
PL3484451T3 (en) Dosage form
GB201704714D0 (en) Pharmaceutical compounds
GB201703876D0 (en) Pharmaceutical combinations
GB201704965D0 (en) Pharmaceutical compounds
GB201703881D0 (en) Pharmaceutical compounds
GB201713653D0 (en) Dosage regimen
IL269239A (en) Pharmaceutical combination comprising ponesimod
GB201521217D0 (en) Dosage regimens
GB201706806D0 (en) Pharmaceutical compounds
GB201711704D0 (en) Pharmaceutical compounds
HRP20220427T8 (en) Pharmaceutical compounds
GB201704966D0 (en) Pharmaceutical compounds
GB201607548D0 (en) Solid dosage form
IL249374A0 (en) Pharmaceutical dosage forms
PT3866775T (en) Dosage regime
GB201720544D0 (en) Dosage regime
GB201720541D0 (en) Dosage regime
GB201720542D0 (en) Dosage regime
GB201720543D0 (en) Dosage regime
GB201710496D0 (en) Dosage regime
GB201710493D0 (en) Dosage regime
GB201710494D0 (en) Dosage regime
GB201710495D0 (en) Dosage regime
GB201709444D0 (en) Dosage regime

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)